RemeGen to acquire global rights to pan-RAS inhibitor for up to 4.87B yuan

RemeGen (荣昌生物) is introducing global rights to a pan-RAS inhibitor, with an upfront payment of 50 million yuan and milestone payments of up to 4.87 billion yuan. The company's shares have risen 26% this year.

Detected & updated continuously · Source: Nebula